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Abstract
Limited therapy options due to antibiotic resistance underscore
the need for optimization of current diagnostics. In some bacterial
species, antimicrobial resistance can be unambiguously predicted
based on their genome sequence. In this study, we sequenced the
genomes and transcriptomes of 414 drug-resistant clinical Pseu-
domonas aeruginosa isolates. By training machine learning classi-
fiers on information about the presence or absence of genes, their
sequence variation, and expression profiles, we generated predic-
tive models and identified biomarkers of resistance to four
commonly administered antimicrobial drugs. Using these data
types alone or in combination resulted in high (0.8–0.9) or very
high (> 0.9) sensitivity and predictive values. For all drugs except
for ciprofloxacin, gene expression information improved diagnostic
performance. Our results pave the way for the development of a
molecular resistance profiling tool that reliably predicts antimicro-
bial susceptibility based on genomic and transcriptomic markers.
The implementation of a molecular susceptibility test system in
routine microbiology diagnostics holds promise to provide earlier
and more detailed information on antibiotic resistance profiles of
bacterial pathogens and thus could change how physicians treat
bacterial infections.
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Introduction
The rise of antibiotic resistance is a public health issue of great-
est importance (Cassini et al, 2019). Growing resistance hampers
the use of conventional antibiotics and leads to increased rates
of ineffective empiric antimicrobial therapy. If not adequately
treated, infections cause suffering, incapacity, and death, and
impose an enormous financial burden on healthcare systems
and on society in general (Alanis, 2005; Gootz, 2010; Fair &
Tor, 2014). Despite growing medical need, FDA approvals of
new antibacterial agents have substantially decreased over the
last 20 years (Kinch et al, 2014). Alarmingly, there are only few
agents in clinical development for the treatment of infections
caused by multidrug-resistant Gram-negative pathogens (Bush &
Page, 2017).
Pseudomonas aeruginosa, the causative agent of severe acute
as well as chronic persistent infections, is particularly problem-
atic. The opportunistic pathogen exhibits high intrinsic antibiotic
resistance and frequently acquires resistance-conferring genes via
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horizontal gene transfer (Lister et al, 2009; Partridge et al, 2018).
Furthermore, the accelerating development of drug resistance due
to the acquisition of drug resistance-associated mutations poses a
serious threat.
The lack of new antibiotic options underscores the need for opti-
mization of current diagnostics. Diagnostic tests are a core compo-
nent in modern healthcare practice. Especially in light of rising
multidrug resistance, high-quality diagnostics becomes increasingly
important. However, to provide information as the basis for infec-
tious disease management is a difficult task. Antimicrobial suscepti-
bility testing (AST) has experienced little change over the years. It
still relies on culture-dependent methods, and as a consequence,
clinical microbiology diagnostics is labor-intensive and slow.
Culture-based AST requires 48 h (or longer) for definitive results,
which leaves physicians with uncertainty about the best drugs to
prescribe to individual patients. This delay also contributes to the
spread of drug resistance (Oliver et al, 2015; Lo´pez-Causape´ et al,
2018).
The introduction of molecular diagnostics could become an alter-
native to culture-based methods and could be critical in paving the
way to fight antimicrobial resistance. Identification of genetic
elements of antimicrobial resistance promises a deeper understand-
ing of the epidemiology and mechanisms of resistance and could
lead to a timelier reporting of the resistance profiles as compared to
conventional culture-based testing. It has been demonstrated that
for a number of bacterial species, antimicrobial resistance can be
highly accurately predicted based on information derived from the
genome sequence (Gordon et al, 2014; Bradley et al, 2015; Moradi-
garavand et al, 2018). However, in the opportunistic pathogen
P. aeruginosa even full genomic sequence information is insuffi-
cient to predict antimicrobial resistance in all clinical isolates (Kos
et al, 2015). Pseudomonas aeruginosa exhibits a profound pheno-
typic plasticity mediated by environment-driven flexible changes in
the transcriptional profile (Do¨tsch et al, 2015). For example,
P. aeruginosa adapts to the presence of antibiotics with the overex-
pression of the mex genes, encoding the antibiotic extrusion
machineries MexAB-OprM, MexCD-OprJ, MexEF-OprN, and
MexXY-OprM. Similarly, high expression of the ampC-encoded
intrinsic beta-lactamase confers antimicrobial resistance (Haenni
et al, 2017; Juan et al, 2017; Goli et al, 2018; Martin et al, 2018).
Those transcriptional responses are frequently fixed in clinical
P. aeruginosa strains, e.g., due to mutations in negative regulators
of gene expression (Frimodt-Møller et al, 2018; Juarez et al, 2018).
Thus, the isolates develop an environment-independent resistance
phenotype. Up-regulation of intrinsic beta-lactamases as well as
overexpression of efflux pumps that contribute to the resistance
phenotype makes gene-based testing a challenge, because it is diffi-
cult to predict from the genomic sequence, which (combinations of)
mutations would lead to an up-regulation of resistance-conferring
genes (Llanes et al, 2004; Ferna´ndez & Hancock, 2012; Schnieder-
jans et al, 2017).
In this study, we investigated whether we can reliably predict
antimicrobial resistance in P. aeruginosa using not only genomic
but also quantitative gene expression information. For this purpose,
we sequenced the genomes of 414 drug-resistant clinical P. aerugi-
nosa isolates and recorded their transcriptional profiles. We built
predictive models of antimicrobial susceptibility/resistance to four
commonly administered antibiotics by training machine learning
classifiers. From these classifiers, we inferred candidate marker
panels for a diagnostic assay by selecting resistance- and susceptibil-
ity-informative markers via feature selection. We found that the
combined use of information on the presence/absence of genes,
their sequence variation, and gene expression profiles can predict
resistance and susceptibility in clinical P. aeruginosa isolates with
high or very high sensitivity and predictive value.
Results
Taxonomy and antimicrobial resistance distribution of 414 DNA-
and mRNA-sequenced clinical Pseudomonas aeruginosa isolates
A total of 414 P. aeruginosa isolates were collected from clinical
microbiology laboratories of hospitals across Germany and at sites
in Spain, Hungary, and Romania (Fig 1A). For all isolates, the
genomic DNA was sequenced and transcriptional profiles were
recorded. This enabled us to use not only the full genomic informa-
tion but also information on the gene expression profiles as an input
to machine learning approaches.
We inferred a maximum likelihood phylogenetic tree based on
variant nucleotide sites (Fig 1B). The tree was constructed by
mapping the sequencing reads of each isolate to the genome of the
P. aeruginosa PA14 reference strain and then aligning the consensus
sequences for each gene. The isolates exhibited a broad taxonomic
distribution and separated into two major phylogenetic groups. One
included PAO1, PACS2, LESB58, and a cluster of high-risk clone
ST175 isolates; the other included PA14, as well as one large cluster
of high-risk clone ST235 isolates. Both groups comprised several
further clades with closely related isolates of the same sequence
type as determined by multilocus sequencing typing (MLST).
Next, we recorded antibiotic resistance profiles for all isolates
regarding the four common anti-pseudomonas antimicrobials, tobra-
mycin (TOB), ceftazidime (CAZ), ciprofloxacin (CIP), and mero-
penem (MEM) (Bassetti et al, 2018; Cardozo et al, 2019; Tu¨mmler,
2019) using agar dilution method. Most isolates of our clinical
isolate collection exhibit antibiotic resistance against these four
antibiotics (Fig 1C, Dataset EV1). One-third had a multidrug-resis-
tant (MDR) phenotype, defined as non-susceptible to at least three
different classes of antibiotics (Magiorakos et al, 2012).
Machine learning for predicting antimicrobial resistance
We used the genomic and transcriptomic data of the clinical
P. aeruginosa isolates to infer resistance and susceptibility pheno-
types to ceftazidime, meropenem, ciprofloxacin, and tobramycin
with machine learning classifiers. For each antibiotic, we included
all respective isolates categorized as either “resistant” or “suscepti-
ble”. For the genomic data, we included sequence variations (single
nucleotide polymorphisms; SNPs, including small indels) and gene
presence or absence (GPA) as features. In total, we analyzed
255,868 SNPs, represented by 65,817 groups with identical distribu-
tions of SNPs across isolates for the same group, and 76,493 gene
families with presence or absence information, corresponding to
14,700 groups of identically distributed gene families. 1,306 of these
gene families had an indel in some isolate genomes, which we
included as an additional feature. We evaluated SNP and GPA
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groups in combination with gene expression information for 6,026
genes (Fig 2).
For each drug, we randomly assigned isolates to a training set that
comprised 80% of the resistant and susceptible isolates, respectively,
and the remaining 20% to a test set. Parameters of machine learning
models were optimized on the training set and their value assessed
in cross-validation, while the test set was used to obtain another
independent performance estimate. As bacterial population structure
A
C
B
Figure 1. Geographic and phylogenetic distribution of 414 clinical Pseudomonas aeruginosa isolates used in this study.
A Geographic sampling site distribution, where circle size is proportional to the number of isolates from a particular location.
B Phylogenetic tree of the clinical isolates and seven reference strains (blue dots). A PA7-like outgroup clade including two clinical isolates is not shown. Abundant high-
risk clones are indicated by green bars. Scale bar: 0.04.
C Antimicrobial susceptibility profiles against the four commonly administered antibiotics tobramycin (TOB), ceftazidime (CAZ), ciprofloxacin (CIP), and meropenem
(MEM) determined by agar dilution according to Clinical & Laboratory Standards Institute Guidelines (CLSI, 2018).
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can influence machine learning outcomes, e.g., it has been shown
before in Escherichia coli that phylo-groups’ specific markers alone
could be used to predict antibiotic resistance phenotypes with accu-
racies of 0.65–0.91, depending on the antibiotic (Moradigaravand
et al, 2018), we also assessed performance while accounting for
population structure based on sequence types through a block cross-
validation approach. We trained several machine learning classifi-
cation methods on SNPs, GPA, and expression features individually
and in combination for predicting antibiotic susceptibility or resis-
tance of isolates and evaluated the classifier performances. We deter-
mined MIC (minimal inhibitory concentration) values of all clinical
isolates with agar dilution according to CLSI guidelines (CLSI, 2018)
to use as the gold standard for evaluation purposes.
We calculated the sensitivity and predictive value of resistance
(R) and susceptibility (S) assignment, as well as the macro F1-score,
as an overall performance measure based on a classifier trained on
a specific data type combination. The sensitivity reflects how good
that classifier is in recovering the assignments of the underlying
gold standard, representing the fraction of susceptible, or resistant,
samples, respectively. The predictive value reflects how trustworthy
the assignments of this particular classifier are, representing the
fraction of correct assignments of all susceptible or resistant
assignments, respectively. The F1-score is the harmonic mean of the
sensitivity and predictive value for a particular class, i.e., suscepti-
ble or resistant. The macro F1-score is the average over the two F1-
scores.
We used the support vector machine (SVM) classifier with a
linear kernel, as in Weimann et al (2016), to predict sensitivity or
resistance to four different antibiotics. Parameters were optimized
in nested cross-validation, and performance estimates averaged over
five repeats of this setup. The combined use of (i) GPA, (ii) SNPs,
and (iii) information on gene expression resulted in high (0.8–0.9)
or very high (> 0.9) sensitivity and predictive values (Fig 3).
Notably, the relative contribution of the different information
sources to the susceptibility and resistance sensitivity strongly
depended on the antibiotic. To assess the effect of the classification
technique, we compared the performance of an SVM classifier with
a linear kernel to that of random forests and logistic regression,
which we and others have successfully used for related phenotype
prediction problems (Asgari et al, 2018; Her & Wu, 2018; Wheeler
et al, 2018). For this purpose, we used the data type combination
with the best macro F1-score in resistance prediction with the SVM.
We evaluated the classification performance in nested cross-valida-
tion and on a held-out test dataset. In addition, we performed a
phylogeny-aware partitioning of our dataset, to assess the phyloge-
netic generalization ability of our technique.
The performance of the SVM in random cross-validation was
comparable to logistic regression (macro F1-score for the SVM:
0.83  0.06 vs. logistic regression: 0.84  0.06), but considerably
better than the random forest classifiers (0.67  0.14;
Appendix Figs S1 and S2, Dataset EV2). The performance on the
held-out dataset was in a comparable range (SVM: 0.87  0.07;
logistic regression: 0.90  0.04; random forest 0.71  0.16). We
furthermore observed similar macro F1-scores inferred in the phylo-
genetically selected cross-validation (SVM: 0.87  0.07; logistic
regression: 0.86  0.07; random forest 0.72  0.13), which
suggests only a minor influence of the bacterial phylogeny on the
classification performance. The performance on the phylogenetically
selected held-out dataset was again comparable, though perfor-
mance for the random forest deteriorated in comparison with the
cross-validation results (SVM: 0.86  0.06; logistic regression
0.83  0.06; random forests 0.56  0.03).
Ciprofloxacin resistance and susceptibility based on SVMs could
be correctly predicted with a sensitivity of 0.92  0.01 and
0.87  0.01, and with simultaneously high predictive values of
0.91  0.01 and 0.90  0.01, respectively, using solely SNP infor-
mation. The sensitivity of 0.80  0.04 and 0.79  0.02 and predic-
tive value of 0.73  0.01 and 0.76  0.02 to predict ciprofloxacin
susceptibility and resistance based exclusively on gene expression
data were also high. However, there was no added value of using
information on gene expression in addition to SNP information for
the prediction of susceptibility/resistance toward ciprofloxacin.
For the prediction of tobramycin susceptibility and resistance,
the machine learning classifiers performed almost equally well
when the three input data types (SNPs, GPA, and gene expression)
were used individually (values > 0.8). SNP information was predic-
tive of tobramycin resistance; however, it did not further improve
the classification performance when combined with the other data
types. GPA information alone was the most important data type for
classifying tobramycin resistance and susceptibility providing
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Figure 2. Training and validating a diagnostic classifier for antimicrobial
susceptibility prediction for four different drugs based on genomic (GPA/
SNPs) and transcriptomic profiles (EXPR).
The best data type combination was determined using 80% of the data in
standard and phylogenetically informed cross-validation (cv) and further
validated on the remaining 20% of the data.
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sensitivity values of 0.84  0.01 and 0.95  0.01 and predictive
values of 0.88  0.01 and 0.93  0.01, respectively. The perfor-
mance of GPA-based prediction increased further when gene expres-
sion values were included (P-value of a one-sided t-test: 0.0069
based on the macro F1-score as determined in repeated cross-valida-
tion; sensitivity values of 0.89  0.01 and 0.94  0.01 for resistance
and susceptibility prediction, respectively, and predictive values of
0.88  0.01 and 0.95  0.01).
For the correct prediction of meropenem resistance/susceptibil-
ity, gene presence/absence was most influential (sensitivity values
of 0.87  0.01 and 0.84  0.01 for resistance and susceptibility
prediction, respectively, and predictive values of 0.92  0.00 and
0.74  0.01). As observed for tobramycin, the use of genome-wide
information on GPA and of information on gene expression in
combination increased the sensitivity to detect resistance as well as
susceptibility to meropenem to 0.91  0.02 and 0.86  0.01 and
CAZ
CIP
M
EM
TO
B
0.4 0.6 0.8
F1−macro
sensitivity S
sensitivity R
F1−macro
sensitivity S
sensitivity R
F1−macro
sensitivity S
sensitivity R
F1−macro
sensitivity S
sensitivity R
EXPR
EXPR+SNPs
GPA
GPA+EXPR
GPA+EXPR+SNPs
GPA+SNPs
SNPS
Figure 3. Evaluation of AMR classification with a support vector machine (R: resistant; S: susceptible) using different performance metrics and data types
(EXPR: gene expression; GPA: gene presence or absence; and SNPs: single nucleotide polymorphisms) or combinations thereof.
Each individual panel depicts the results for one of four different anti-pseudomonal antibiotics (CAZ, CIP, MEM, and TOB). The solid vertical line in the box plots represents
the median, the box limits depict the 25th and 75th percentile, and the lower and upper hinges include values within 1.5 times the interquartile range. Values outside that
range were plotted as solid dots.
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the predictive values to 0.93  0.01 and 0.81  0.03, respectively
(P-value of a one-sided t-test: 0.004).
For ceftazidime, using only information on gene presence/
absence revealed a sensitivity of susceptibility/resistance prediction
of 0.69  0.01 and 0.66  0.01, and predictive values of
0.66  0.01 and 0.67  0.01, respectively. Adding gene expression
information considerably improved the performance of susceptibil-
ity and resistance sensitivity to 0.83  0.02 and 0.81  0.02 and
predictive values of 0.81  0.02 and 0.83  0.01 (P-value of a one-
sided t-test 7.1 × 107). In summary, for tobramycin, ceftazidime,
and meropenem combining GPA and expression information gave
the most reliable classification results, whereas for ciprofloxacin we
found that only using SNPs provided the best performance (Table 1
and Dataset EV3). Thus, for the remainder of the manuscript, we
will focus on the results obtained with classifiers trained on those
data type combinations.
A candidate drug resistance marker panel
We determined the minimal number of molecular features required
to obtain the highest macro F1-score for each drug. We inferred the
number of features contributing to the classification from the
number of non-zero components of the SVM weight vectors, using a
standard cross-validation setup. For each value of the C parameter,
which controls the amount of regularization imposed on the model,
the cross-validation procedure was repeated five times (Fig 4,
Dataset EV4). Performance of antimicrobial resistance prediction
peaked for the candidate classifiers using between 50 and 100
features. Notably, the ciprofloxacin classifier required only two
SNPs until the learning curve performance was almost saturated,
whereas classifiers of drugs that included expression and gene
presence/absence markers required more features (> 50) to reach
saturation.
Next, we determined the C parameter resulting in the least
complex SVM model within one standard deviation of the peak
performance, i.e., with the best macro F1-score and as few as possi-
ble features for each drug (Friedman et al, 2001). We chose our
candidate marker panel for each drug as the set of all non-zero
features and designated the respective model as the most suitable
diagnostic classifier. We used SNP information for ciprofloxacin
resistance and susceptibility prediction and the combination of GPA
and expression features for tobramycin, meropenem, and ceftazi-
dime. We refer to each of these classifiers as the candidate classifier
for susceptibility and resistance prediction for a particular drug.
The ciprofloxacin candidate marker panel contained 50 SNPs.
The meropenem, ceftazidime, and tobramycin marker lists
consisted of 93, 37, and 59 expression and GPA features. The
complete list of candidate markers for the prediction of resistance
against the four antibiotics is given in Dataset EV5. This list
includes the candidate markers of the three input features namely
GPA, gene expression, and SNPs alone and in combination.
Table 2 is a shortlist of the panel markers for each drug based on
the data combination that had allowed us to train the most reli-
able classifier.
To test the performance of the candidate marker panel-based
classifiers on an independent set of clinical P. aeruginosa isolates,
we used them to predict antibiotic resistance for the samples of the
test dataset (Fig 5, Dataset EV6). On this held-out data, we obtained
an F1-sore for all drugs that was similarly high as before: Namely
this was 0.95 for meropenem, 0.77 for ceftazidime, and 0.96 for
tobramycin, using gene expression and gene presence/absence
features, and 0.87 for ciprofloxacin using SNP information. These
results indicate that the diagnostic classifiers have good generaliza-
tion abilities when applied to new samples. We observed more vari-
ability across drugs than in nested cross-validation, which is
expected due to the smaller size of the test set.
Improvement of assignment accuracy with increasing
sample numbers
We next investigated how prediction performance depended on the
number of samples used for classifier training. We trained the SVM
classifiers on random subsamples of different sizes of the full
dataset with 414 isolates. For each model, we recorded the macro
F1-score in five repeats of 10-fold nested cross-validation (Fig 6).
The classification performance saturates for all our classifiers well
before using all available training samples, suggesting that when
adding more isolates for resistance classification, the classification
performance would improve only very slowly. Markers potentially
remaining undiscovered in our study might have very small effect
sizes, requiring much larger dataset sizes for their detection. Inter-
estingly, the number of samples required until the performance
curve plateaued depends on the drugs and data types used. For
ciprofloxacin, the performance of susceptibility/resistance predic-
tion based on SNPs saturated quickly, likely due to the large impact
of the known mutations in the quinolone resistance-determining
region (QRDR), whereas the classifiers for the other three drugs,
which were trained on expression and gene presence/absence infor-
mation, required more samples until the F1-score plateaued. For
these classifiers, the dispersion of the macro F1-score for subsets of
the data with fewer samples is also considerably higher than for the
ciprofloxacin SNP models.
Table 1. Performance of support vector machine (SVM) classifier to predict sensitivity or resistance to four different antibiotics.
Antibiotic
Markers
used
Sensitivity
(resistance)
Sensitivity
(susceptibility)
Predictive value
(resistance)
Predictive value
(susceptibility) F1-score
Number
of markers*
CAZ GPA+EXPR 0.83  0.02 0.81  0.02 0.81  0.02 0.83  0.01 0.82  0.01 37
TOB GPA+EXPR 0.89  0.01 0.94  0.01 0.88  0.01 0.95  0.01 0.92  0.01 59
MEM GPA+EXPR 0.91  0.02 0.86  0.01 0.93  0.01 0.81  0.03 0.87  0.01 93
CIP SNPs 0.92  0.01 0.87  0.01 0.91  0.01 0.90  0.01 0.90  0.01 50
*The number of markers indicates the number of (combined) features that resulted in the least complex SVM model within one standard deviation of the peak
performance, i.e., with the best macro F1-score and as few as possible features for each drug.
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Performance estimation stratifying by sequence type suggests
some influence of the bacterial phylogeny on the prediction
In P. aeruginosa, different phylo-groups might contain different
antibiotic resistance genes or mutations alone or in
combinations. Thus, if there was an association of distinct resis-
tance-conferring genes with certain phylo-groups, our machine
learning approach might identify markers that distinguish
between different phylo-groups rather than between susceptible
and resistant clinical isolates. In Figs EV1–EV4, we show
CAZ CIP MEM TOB
#m
arke
rs
F1−score_m
acro
0.001 0.01 0.1 0.50.001 0.01 0.1 0.50.001 0.01 0.1 0.50.001 0.01 0.1 0.5
0
50
100
150
0.4
0.6
0.8
SVM C parameter
optimal model
non−optimal model
Figure 4. The number of features used by the support vector machine classifier (top panels) and corresponding classification performance (bottom panels)
varies with the hyperparameter C.
The C parameter is inversely related to the number of markers being included in the model, i.e., lower values for the C parameter yield models with less features. The SVM
resistance/susceptibility classifier was evaluated in five repeats of 10-fold nested cross-validation. Each panel depicts the results for a different drug (CAZ, CIP, MER, and TOB)
based on the best data type combination (GPA+EXPR/SNPs). The model with the fewest features within one standard deviation of the maximal performance was selected as
the most suitable diagnostic classification model (red) (Dataset EV5). The solid vertical line in the box plots represents the median, the box limits depict the 25th and 75th
percentile, and the lower and upper hinges include values within  1.5 times the interquartile range. Values outside that range were plotted as solid dots.
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Table 2. The top 15 candidate markers ranked according to the contribution of each marker to the support vector machine classifier for each drug
based on the best performing combination of data types.
Drug Data type PA14/CARD gene_id PA14/CARD gene_acc Prokka/Roary gene_id SNP position
TOB (GPA_EXPR) GPA A7J11_00271 qacEdelta1 emrE
GPA A7J11_02078 sul1 folP_2_indel
GPA PA14_04410 ptsP ptsP
GPA group_282
GPA PA14_20840 group_14073
GPA group_20477
EXPR PA14_15450 traJ
GPA PA14_15100 mepM_1
GPA A7J11_02078 sul1 folP_2
GPA group_8948
GPA group_51714
EXPR PA14_38410 amrB
GPA PA14_18565 alg8 alg8
GPA group_3462
GPA group_17749
MEM (GPA_EXPR) GPA group_596_indel/oprD_1
GPA PA14_51880 oprD oprD_4_indel
EXPR PA14_46070 gbuA
EXPR PA14_05550 oprM
GPA group_3638
EXPR PA14_51880 oprD
GPA group_6217/pknK_1
EXPR PA14_05540 mexB
EXPR PA14_07630
EXPR PA14_63090 lldD
GPA PA14_11960 yabI_indel
EXPR PA14_70940 betA
GPA group_6280
GPA group_15876
GPA group_10960
CIP (SNPs) SNP PA14_23260 gyrA 2015001
SNP PA14_65605 parC 5845617
SNP PA14_55600 4947631
SNP PA14_56040 5004892
SNP PA14_30960 traG 2690138
SNP PA14_31010 2694327
SNP PA14_29390 2545634
SNP PA14_41560 nasA 3710561
SNP PA14_18260 fruK 1567193
SNP PA14_30910 trbE 2685860
SNP PA14_30960 traG 2689741
SNP PA14_59210 5274257
SNP PA14_44640 3974007
SNP PA14_41110 3665768
SNP PA14_15460 merA 1310089
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susceptibility and resistance of each isolate in the context of the
phylogenetic tree as predicted by the diagnostic classifier and
based on AST for each of the drug. To assess whether our
predictive markers are biased by the phylogenetic structure of
the clinical isolate collection, we assessed classification robust-
ness in a block cross-validation approach. Here, isolates of
phylo-groups with differing sequence types as determined by
MLST were grouped into blocks and all isolates of a given block
were only allowed to be either in the training or test folds
(Figs 2 and 5). In addition, instead of using a random assign-
ment of strains into test and training dataset, we analyzed the
performance only allowing strains in a test dataset corresponding
to the block cross-validation training dataset with sequence types
that were not already included in this training dataset. For all
classifiers including our candidate diagnostic classifiers, we
found that the block cross-validation performance estimates were
slightly lower than those obtained using a sequence type-
unaware estimation (F1-score difference between ~ 0.03 and 0.05
for the diagnostic classifiers). This was particularly apparent for
some suboptimal data type combinations, such as for predicting
tobramycin resistance using SNPs or gene expression, where a
substantially lower discriminative performance was achieved in
block- compared to random cross-validation (macro F1-score dif-
ference > 0.1, Dataset EV3). Interestingly, we observed that the
ranking of the performance by data type remained almost identi-
cal for all drugs. Overall, the performance estimates we obtained
using this phylogenetically insulated test dataset were compara-
ble to the block cross-validation estimates, only tobramycin resis-
tance prediction using classifiers trained fully or partly on SNPs
dropped considerably in performance.
In summary, this confirmed that the various P. aeruginosa
phylogenetic subgroups possess similar mechanisms and molecular
markers for the resistance phenotype and that the identified mark-
ers are largely distinctive for resistance/susceptibility instead of
phylogenetic relationships using most data type combinations.
Despite the observed independence of the presence of genetic
resistance markers and bacterial phylogeny, for some antibiotics
and data types we also found a non-negligible phylo-group-depen-
dent performance effect. This underlines the importance of assess-
ing the impact of the phylogeny on the antimicrobial resistance
prediction.
Misclassified isolates are more frequent near the
MIC breakpoints
We tested whether we could detect an overrepresentation of
misclassified samples among the samples with a MIC value close to
the breakpoints compared to samples with higher or lower MIC
values, selecting samples from equidistant intervals (in log space)
around the breakpoint. We report only the strongest overrepresen-
tation for each drug after multiple testing correction. For ciproflox-
acin, significantly more samples with a MIC between 0.5 and 8
were misclassified (31 of 139 samples (22%)) than samples with a
MIC smaller than 0.5 or larger than 8 (7 of 219 samples (3%))
(Fisher’s exact test with an FDR-adjusted P-value of 6.2 × 108;
Fig 7). For ceftazidime, we found that 46 of 177 samples (26%)
with a MIC between 4 and 64 were misclassified whereas only 21 of
157 (13%) of samples with a MIC smaller or higher than those
values were misclassified (adjusted P-value: 0.014). For mero-
penem, we found that 26 of 207 samples (13%) with a MIC
between 1 and 16 were misclassified, but only 8 of 147 (5%) of all
samples with a MIC smaller or higher than those values were
misclassified (adjusted P-value: 0.05). For tobramycin, no signifi-
cant difference was found.
Table 2 (continued)
Drug Data type PA14/CARD gene_id PA14/CARD gene_acc Prokka/Roary gene_id SNP position
CAZ (GPA_EXPR) EXPR PA14_10790 ampC
GPA A7J11_02078 sul1 folP_2
GPA group_8955
EXPR PA14_48900
GPA PA14_00810 group_13626
EXPR PA14_15770
GPA group_3462
GPA PA14_33690 pvdE yojI
GPA group_23010
GPA petE_indel
EXPR PA14_31240
EXPR PA14_53500
GPA group_5517
GPA PA14_22650 group_14516_indel
GPA group_63043
For gene presence/absence (GPA) markers, we provide the gene id and accession based on PA14 reference genome gene family member or based on the
Comprehensive Antibiotic Resistance Database (CARD) (Jia et al, 2017). Otherwise, we include the gene name or id of each marker as generated by the bacterial
genome annotation tool Prokka (Seemann, 2014) and protein family clustering software Roary (Page et al, 2015). Expression markers are based on the PA14
genome, too. For short nucleotide polymorphisms (SNPs), we report the genome position in the reference PA14 genome.
ª 2020 The Authors EMBO Molecular Medicine 12: e10264 | 2020 9 of 19
Ariane Khaledi et al EMBO Molecular Medicine
Discussion
One of the most powerful weapons in the battlefield of drug-resistant
infections is rapid diagnostics of resistance. Earlier and more detailed
information on the pathogens’ antimicrobial resistance profile has the
potential to change antimicrobial prescribing behavior and improve
the patient’s outcome. The demand for faster results has initiated
investigation of molecular alternatives to today’s culture-based clini-
cal microbiology procedures. However, for the successful implemen-
tation of robust and reliable molecular tools, it is critical to identify
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Figure 5. Performance of the support vector machine (SVM) classifier for antimicrobial resistance and susceptibility prediction for different data types,
different drugs, and different evaluation schemes.
The SVM performance was summarized by the F1-score and is shown for standard cross-validation (standard_cv, blue) and cross-validation using phylogenetically
related blocks of isolates (block_cv, red) based on the training dataset (80% of the isolates) and for the validation dataset (green; 20% of the isolates). EXPR: gene
expression; GPA: gene presence and absence with indel information. SNPs: short nucleotide polymorphisms. The solid vertical line in the box plots represents the
median, the box limits depict the 25th and 75th percentile, and the lower and upper hinges include values within  1.5 times the interquartile range. Values outside
that range were plotted as solid dots.
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the entirety of the molecular determinants of resistance. Failure to
detect resistance can lead to the administration of ineffective or
suboptimal antimicrobial treatment. This has direct consequences for
the patient and poses significant risks especially in the critically ill
patient. Conversely, failing to identify susceptibility may result in the
avoidance of a drug despite the fact that it would be suitable to treat
the pathogen, in the extreme case leading to patient death due to a
lack of known treatment options. Overtreatment could also be a
consequence and the needless use of broad-spectrum antibiotics. This
drives costs in the hospital, puts patients at risk for more severe side
effects, and may contribute to the development of drug resistance by
applying undesired selective pressures.
In this study, we show that without any prior knowledge on the
molecular mechanisms of resistance, machine learning approaches
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Figure 6. Classification performance improves and plateaus with the number of training samples used.
A support vector machine-based resistance/susceptibility classifier was trained on differently sized and randomly drawn subsamples from our isolate collection and
evaluated in five repeats of a 10-fold nested cross-validation. Each panel depicts the results for a different drug (CAZ, CIP, MEM, and TOB) based on the best data type
combination (GPA+EXPR/SNPs). The solid vertical line in the box plots represents the median, the box limits depict the 25th and 75th percentile, and the lower and upper
hinges include values within  1.5 times the interquartile range. Values outside that range were plotted as solid dots.
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using genomic and transcriptomic features can provide high antibi-
otic resistance assignment capabilities for the opportunistic
pathogen P. aeruginosa. The performance of drug resistance predic-
tion was strongly dependent on the antibiotic.
Ciprofloxacin resistance and susceptibility prediction mostly
relied on SNP information. Particularly, two SNPs in the quinolone
resistance-determining region (QRDR) of gyrA and parC had the
strongest impact on the classification (Dataset EV3). This is an
expected finding as quinolone antibiotics act by binding to their
targets, gyrase, and topoisomerase IV (Bruchmann et al, 2013); and
target-mediated resistance caused by specific mutations in the encod-
ing genes is the most common and clinically significant form of resis-
tance (del Barrio-Tofin˜o et al, 2017). Although the sensitivity to
predict resistance and susceptibility from only gene expression data
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Figure 7. Number of samples misclassified and correctly predicted by the support vector machine resistance and susceptibility classifier (SVM) grouped by
their minimum inhibitory concentration.
Each panel depicts the results for a different anti-pseudomonal drug (CAZ: ceftazidime; CIP: ciprofloxacin; MEM: meropenem; TOB: tobramycin) for the best data type
combination (GPA+EXPR/SNPs). Misclassified and correctly classified samples for the training dataset (80%) were inferred in a 10-fold cross-validation. An SVM trained on
the training dataset was used to predict resistance/susceptibility of the test samples (20%). The number of misclassified samples in the training (80%) and test set was
aggregated.
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were also high toward ciprofloxacin, there was no added value of
using information on gene expression in addition to SNP informa-
tion. Nevertheless, for the design of a diagnostic test system, it might
be of value to include also gene expression information as a fail-safe
strategy. Interestingly, among the gene expression classifiers that
were associated with ciprofloxacin susceptibility/resistance, we
found prtN, which is involved in pyocin production. Enhanced
pyocin production is, as the SOS response, induced under DNA-
damaging stress conditions (Migliorini et al, 2019) and was recently
reported to contribute to ciprofloxacin resistance (Fan et al, 2019).
For the prediction of tobramycin susceptibility and resistance,
the machine learning classifiers performed almost equally well
when the three input data types (SNPs, GPA, and gene expression)
were used individually (sensitivity and predictive values > 0.8).
Remarkably, the combined use of the GPA and the gene expres-
sion datasets improved the classification performance. Although
SNP information also was predictive of tobramycin resistance, it
did not further improve the classification performance when
combined with the other feature types. GPA information alone was
the most important data type for classifying tobramycin resistance
or susceptibility. The majority of aminoglycoside-resistant clinical
isolates harbor genes encoding for aminoglycoside-modifying
enzymes (AMEs). The AMEs are very diverse but are usually
encoded by genes located on mobile genetic elements, including
integrons and transposons. In accordance, the presence of respec-
tive markers that indicate the presence of these mobile elements
was found to be strongly associated with tobramycin resistance
(e.g., qacEdelta1, sul1, or folP). However, the most influential
discriminator was the presence of the emrE gene. EmrE has been
described to directly impact on aminoglycoside resistance by medi-
ating the extrusion of small polyaromatic cations (Li et al, 2003).
Second, we identified the presence of ptsP (encoding phospho-
enolpyruvate protein phosphotransferase) as an important marker
for tobramycin resistance. This gene has previously already been
associated with tobramycin resistance in a transposon mutant
library screen (Schurek et al, 2008).
The performance of GPA-based prediction increased further
when gene expression values were included. We found, e.g., amrB
(mexY), which encodes a multidrug efflux pump known to confer to
aminoglycoside resistance (Westbrock-Wadman et al, 1999; Lau
et al, 2014), as one of the top candidates within the marker panel.
This confirms that expression of efflux pumps is an important bacte-
rial trait that drives the resistance phenotype in P. aeruginosa.
Tobramycin resistance/susceptibility was also associated with an
altered expression or SNPs within genes involved in type 4 pili
motility (pilB pilV2, pilC, and pilH) and the type three secretion
system (pcr genes). Although the connection to tobramycin resis-
tance might be not exactly obvious, it has been proposed that
surface motility can lead to extensive multidrug adaptive resistance
as a result of the collective dysregulation of diverse genes (Sun et al,
2018).
For the correct prediction of meropenem resistance/susceptibil-
ity, gene presence/absence was most influential. Interestingly, in
contrast to tobramycin resistance classification, we observed a
substantial accumulation of indels in specific marker genes. Among
these marker genes were ftsY, involved in targeting and insertion of
nascent membrane proteins into the cytoplasmic membrane, czcD,
encoding a cobalt–zinc–cadmium efflux protein, and oprD.
Inactivation of the porin OprD is the leading cause of carbapenem
non-susceptibility in clinical isolates (Ko¨hler et al, 1999). As
expected, also a decreased oprD gene expression in the resistant
group of isolates was identified as an important discriminator. Inter-
estingly though, the most important gene expression marker was
not the down-regulated oprD, but an up-regulation of the gene
gbuA, encoding a guanidinobutyrase in the arginine dehydrogenase
pathway, in the meropenem-resistant group of isolates. It is known
that arginine metabolism plays a critical role during host adaptation
and persistence (Hogardt & Heesemann, 2013). Interestingly, it was
also described before that GbuA is linked to virulence factor expres-
sion and the production of pyocyanin (Jagmann et al, 2016). Our
results indicate that up-regulation of gbuA might be the result of a
non-fully functional OprD porin. Since OprD has been shown to be
involved in arginine uptake (Tamber & Hancock, 2006), one might
speculate that lack of arginine due to a non-functional OprD triggers
the expression of gbuA to compensate for the fitness defect of the
oprD mutant.
Furthermore, components encoding the MexAB-OprM efflux
pump (mexB, oprM) were identified as important features associated
with resistance. This efflux pump is known to export beta-lactams,
including meropenem (Li et al, 1995; Srikumar et al, 1998; Cler-
mont et al, 2001).
As observed for tobramycin, the correct prediction of ceftazidime
resistance/susceptibility was strongly influenced by both gene
expression values (here ampC, fpvA, pvdD, and algF) and gene pres-
ence/absence (including the presence of mobile genetic elements).
While AmpC is a known intrinsic beta-lactamase, able to hydrolyze
cephalosporins (Lister et al, 2009), the association of ceftazidime
resistance with expression variations in fpvA, pvdD, and algF,
involved in the uptake of iron and the production of alginate,
respectively, is less clear. Interestingly, sequence variations in regu-
lators such as AmpR, AmpG, AmpD (including AmpD homologs),
and mpl and alteration in penicillin-binding proteins such as PBP4
(dacB) have been described to trigger constitutive ampC overexpres-
sion (Bagge et al, 2002; Juan et al, 2005, 2006; Schmidtke &
Hanson, 2008; Moya et al, 2009; Balasubramanian et al, 2012;
Cabot et al, 2018). AmpR, however, does not only control ampC
expression but has also been described to be a global regulator of
resistance and virulence in P. aeruginosa and to be an important
acute–chronic switch regulator (Balasubramanian et al, 2015). As
such, AmpR is also involved in the regulation of alginate production
as well as iron acquisition via siderophores. This might explain why
expression of fpvA, pvdD, and algF was found to be associated with
ceftazidime resistance.
Since we did not identify any of the previously described
sequence variations in the various regulators of ampC expression by
the use of the machine learning approach, we re-analyzed them in
more detail. Interestingly, we identified a small number of isolates
in the resistant group (11 of 165) harboring an R504C substitution
in the gene ftsI (PBP3). Mutations in PBP3 have been described to
represent an AmpC-independent resistance evolution in vitro and
occur upon beta-lactam treatment in vivo (Cabot et al, 2016, 2018;
Lo´pez-Causape´ et al, 2017). Particularly, the R504C substitution has
been found in clinical cystic fibrosis isolates and is contributing to
ceftazidime resistance (Lo´pez-Causape´ et al, 2017). However, all
but three of our CAZ-resistant isolates with a R504C mutation in ftsI
likewise showed a strong ampC overexpression, most likely
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explaining why ftsI was not identified as a discriminative marker
in our analysis, despite clearly harboring resistance-associated
mutations.
Adding information on the gene expression considerably
improved the performance of susceptibility and resistance sensitiv-
ity for ceftazidime, which was not observed in a similar scale for
any other antibiotic.
Interestingly, although we recognized widely overlapping resis-
tance profiles for all antibiotics (Fig EV5), we did not observe a
strong co-resistance bias in the identified markers. For example,
among the best performing classifiers for meropenem, ceftazidime,
and tobramycin, there were only overlapping markers between
ceftazidime and tobramycin. These included expression of
PA14_15420 and presence of A7J11_02078/sul1/folP_2, group_282,
group_3462, and group_5517 which account for 5/59 and 5/37 of
the total features or 14.7%/17.1% of the total weight of the ceftazi-
dime and tobramycin SVM classifiers, respectively. Group_282,
group_3462, and group_5517 genes are hypothetical genes. Sul1,
which is located on mobile elements (usually class 1 integrons),
could indicate that the shared signal of the tobramycin and ceftazi-
dime classifiers is due to resistance genes being found on the same
resistance cassettes, as class 1 integrons carrying beta-lactamases as
well as aminoglycoside-modifying enzymes are frequently detected
(Poirel et al, 2001; Fonseca et al, 2005).
In conclusion, we demonstrate that extending the genetic
features (SNPs and gene presence/absence) with gene expression
values is key to improving performance. Thereby, relative contribu-
tion of the different categories of biomarkers to the susceptibility
and resistance sensitivity strongly depended on the antibiotic. This
is in stark contrast to the prediction of antibiotic resistance in many
Enterobacteriaceae, where knowledge of the presence of resistance-
conferring genes, such as beta-lactamases, is usually sufficient to
correctly predict the susceptibility profiles. However, analysis of the
gene expression marker lists revealed that the resistance phenotype
in the opportunistic pathogen P. aeruginosa (and possibly also in
other non-fermenters) is multifactorial and that alterations in gene
expression can alter the resistance phenotype quite substantially.
Intriguingly, we found that the performance of our classifiers
improved if the isolates exhibited MIC values that were not close to
the breakpoint. This was especially apparent for ciprofloxacin. It has
been demonstrated that patients treated with levofloxacin for blood-
stream infections caused by Gram-negative organisms for which MICs
were elevated, yet still in the susceptible category, had worse
outcomes than similar patients infected with organisms for which
MICs were lower (Defife et al, 2009). A possible explanation for treat-
ment failure could be the presence of first-step mutations in gyrA that
lead to MIC values near the breakpoint. If subjected to quinolones,
those isolates can rapidly acquire second-step mutations in parC that
would then exhibit a fully resistant phenotype. An additional explana-
tion might also be that generally, MICs have a low level of repro-
ducibility (Turnidge & Paterson, 2007; Juan et al, 2012; Javed et al,
2018). A non-accurate categorization due to uncertainty in testing
near the MIC breakpoint can explain failure in the assignment of drug
resistance by the machine learning classifiers.
Capturing the full repertoire of markers that are relevant for
predicting antimicrobial resistance in P. aeruginosa will require
further studies, to expand the predictive power of the established
marker lists. The remaining misclassified samples in our study on
the basis of these marker lists represent a valuable resource to
uncover further spurious resistance mutations.
The broad use of molecular diagnostic tests promises more
detailed and timelier information on antimicrobial-resistant pheno-
types. This would enable the implementation of early and more
targeted, and thus more effective antimicrobial therapy for
improved patient care. Importantly, a molecular assay system can
easily be expanded to test for additional information such as the
clonal identity of the bacterial pathogen or the presence of critical
virulence traits. Thus, availability of molecular diagnostic test
systems can also provide prognostic markers for disease outcome
and give valuable information on the clonal spread of pathogens in
the hospital setting. However, to realize the full potential of the
envisaged molecular diagnostics, clinical studies will be needed to
demonstrate that broad application of such test systems will have
an impact in clinical decision-making, provide the basis for more
efficient antibiotic use, and also decrease the costs of care.
Materials and Methods
Strain collection and antibiotic resistance profiling
Our study included 414 clinical P. aeruginosa isolates provided by
different clinics or research institutions: 350 isolates were collected
in Germany (138 at the Charite´ Berlin (CH), 89 at the University
Hospital in Frankfurt (F), 39 at the Hannover Medical School
(MHH), and 84 at different other locations). Sixty-two isolates were
provided by a Spanish strain collection located at the Son Espases
University Hospital in Palma de Mallorca (ESP), and two samples
originated from Hungary and Romania, respectively.
All clinical isolates were tested for their susceptibility toward the
four common anti-pseudomonas antibiotics tobramycin (TOB),
ciprofloxacin (CIP), meropenem (MEM), and ceftazidime (CAZ).
Minimal inhibitory concentration (MIC) testing and breakpoint
determination were performed in agar dilution according to Clinical
& Laboratory Standards Institute (CLSI) Guidelines (CLSI, 2018).
MIC testing was performed in triplicates for all isolates. If results
varied, up to five replicates were used. Only isolates with at least
three matching results were included in the study. Most of the
isolates were categorized as multidrug-resistant (resistant to three or
more antimicrobial classes, Dataset EV1). As reference for differen-
tial gene expression and sequence variation analysis, the UCBPP-
PA14 strain was chosen.
Colony screening
To rule out possible contaminations, all isolates were continuously
re-streaked at least twice from single colonies. Only isolates with
reproducible outcomes in phenotypic tests were included in the final
panel, which furthermore passed DNA sequencing quality control
(> 85% sequencing reads mapped to P. aeruginosa UCBPP-PA14
reference genome, total read GC content of 64–66%).
RNA sequencing
For comparable whole-transcriptome sequencing, all clinical isolates
and the UCBPP-PA14 reference strain were cultivated at 37°C in LB
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broth and harvested in RNAprotect (Qiagen) at OD600 = 2. Sequenc-
ing libraries were prepared using the ScriptSeq RNA-Seq Library
Preparation Kit (Illumina), and short read data (single end, 50 bp)
were generated on an Illumina HiSeq 2500 machine creating on
average 3 million reads per sample. The 414 samples were distrib-
uted across 24 independent sequencing pools. We assessed possible
batch effects using triplicates of the PA14-wt (Appendix Fig S3). The
majority of the genome was very stably expressed across the repli-
cates (Pearson correlation coefficient ≥ 0.94).
The reads were mapped with Stampy [v1.0.23; (Lunter & Good-
son, 2011)] to the UCBPP-PA14 reference genome (NC_008463.1),
which is available for download from the Pseudomonas Genome
database (http://www.pseudomonas.com). Mapping and calcula-
tion of reads per gene (rpg) values were performed as described
previously (Khaledi et al, 2016). Expression counts were log-trans-
formed (to deal with zero values, we added one to the expression
counts).
DNA sequencing
Sequencing libraries were prepared from genomic DNA using the
NEBNext Ultra DNA Library Prep Kit (New England Biolabs) and
sequenced in paired-end mode on Illumina HiSeq or MiSeq machi-
nes, generating either 2 × 250 or 2 × 300 bp reads. On average,
2.89 million reads were generated per isolate (ranging from 653,062
to 21,086,866 reads with at least 30 times total genome coverage per
isolate). All reads were adapter and quality-clipped using fastq-mcf
(Andrews, 2010).
SNP calling
DNA sequencing reads were mapped with Stampy as described
above (see RNA sequencing). For variant calling, SAMtools, v0.1.19
(Li et al, 2009), was used. We noticed that sometimes sequencing
errors (particularly around indels) tended to influence calling accu-
racy (e.g., a SNP was called although the nucleotide chance
appeared only in a fraction of the reads). For correction of these
obvious errors, we implemented an additional step where nucleo-
tide positions were converted into the most likely sequence accord-
ing to the most frequently occurring nucleotide at this position.
Phylogeny
Paired-end reads (read length 150, fragment size 200) of eight
reference genomes were simulated using art_illumina (v2.5.8)
with the default error profile at 20-fold coverage (Huang et al,
2012). Together with our 414 clinical isolates, the sequencing
reads were mapped to the coding regions of reference genome
UCBPP-PA14 by BWA-MEM (v0.7.15) (preprint: Li, 2013).
SAMtools (v1.3.1) (Li et al, 2009) and BamTools (Barnett et al,
2011) (v2.3.0) were used for indexing and sorting the aligned
reads, respectively, followed by variant calling using FreeBayes
(v1.1.0) (preprint: Garrison & Marth, 2012). The consensus coding
sequences were computed by BCFtools (v1.6) (Li, 2011) and then
sorted into families by corresponding reference regions. A gene
family was excluded if the gene sequence of any of its member
differed by more than 10% in lengths as compared to the length
of the reference genome gene family. Totally, 5,936 families were
retained. The sequences of each family were aligned by MAFFT
(v7.310) (Katoh & Standley, 2013), and the alignments were
concatenated. SNP sites that were only present in a single isolate
were removed from the alignment. The final alignment was
composed of 558,483 columns, and the approximately maximum
likelihood phylogeny was then inferred by FastTree (v2.1.10,
double precision) (Price et al, 2010).
Pan-genome analysis and indel calling
The trimmed reads were assembled with SPAdes, v.3.0.1, using
the –careful parameter (Bankevich et al, 2012). The assembled
genomes were annotated using Prokka (v1.12) (Seemann, 2014)
using the metagenome mode of Prokka for gene calling, as we had
noticed that genes on resistance cassettes were often missed by the
standard isolate genome gene calling procedure. The gene
sequences were clustered into gene families using Roary (Page
et al, 2015). We observed that Roary frequently clustered together
gene sequences of drastically varying lengths due to indels or start
and stop codon mutations in those gene sequences and frequently
also splits orthologous genes into more than one gene family. To
overcome this behavior, we modified Roary to require at least
95% alignment coverage in the BLAST step (https://github.com/
hzi-bifo/Roary).
For matching the Prokka annotation and the reference annota-
tion of the PA14 strain, we used bedtools (Quinlan, 2014) to search
for exact overlaps of the gene coordinates. In a second step, we
identified all Roary gene families that contained a PA14 gene. To
identify insertions and deletions in the Roary gene families, we
extracted nucleotide sequences for each gene family and used
MAFFT (Katoh & Standley, 2013) to infer multiple sequence align-
ments. We restricted this analysis to gene families present in at
least 50 strains. Then, we used MSA2VCF (https://github.com/lin
denb/jvarkit/) for calling variants in the gene sequences and
restricted the output to insertion and deletions of at least nine
nucleotides.
Support vector machine classification
For applying cross-validation, the dataset was split once randomly
and once phylogenetically informed (see below) into k-folds (k set
to 10, unless specified otherwise). Classifier hyperparameters were
optimized on a k  1 fold-sized partition, and performance of the
optimally parameterized method was determined on the left out k
fraction of the data. This was performed for all possible k partitions,
assignments summarized, and final performance measures obtained
by averaging.
Comparison of different machine learning classifiers
We used the training set for hyperparameter tuning of the classi-
fiers, i.e., a linear SVM, RF, and LR, optimizing the F1-score in 10-
fold cross-validation and then evaluated the best trained classifier
on the held-out set. The expression features (EXPR) and any combi-
nation of features with another data type (GPA and SNPs) were
transformed to have zero mean and unit variance, whereas binary
features (GPA, SNPs, and GPA+SNPs) were not transformed. The
RF classifier was optimized for the macro F1-score over different
ª 2020 The Authors EMBO Molecular Medicine 12: e10264 | 2020 15 of 19
Ariane Khaledi et al EMBO Molecular Medicine
hyperparameters: (i) the number of decision trees in the ensemble,
(ii) the number of features for computing the best node split, (iii)
the function to measure the quality of a split, and (iv) the minimum
number of samples required to split a node. The logistic regression
and the linear SVM were optimized for the macro F1-score over: (i)
the C parameter (inverse to the regularization strength) and (ii)
class weights (to be balanced based on class frequencies or to be
uniform over all classes). Subsequently, we measured the perfor-
mance of the optimized classifiers over accordingly generated, held-
out sets of samples.
In clinical practice, P. aeruginosa strains isolated from patients
are likely to include sequence types that are already part of our
isolate collection. To obtain a more conservative estimate of the
performance of the antimicrobial susceptibility prediction, we also
validated the classifiers on a held-out dataset composed of entirely
new sequence types and also selected the folds in cross-validation
to be non-overlapping in terms of their sequence types (block cross-
validation). For partitioning the isolate collection into sequence
types, we used spectral clustering over the phylogenetic similarity
matrix (preprint: von Luxburg, 2007). We obtained this matrix by
applying a Gaussian kernel over the matrix of distances between
isolates based on the branch lengths in the phylogenetic tree.
Multilocus sequence typing
Consensus fastq files for each isolate were created with SAMtools to
extract the seven P. aeruginosa relevant MLST gene sequences
(acsA, aroE, guaA, mutL, nuoD, ppsA, and trpE). Sequence type
information was obtained from the P. aeruginosa MLST database
(https://pubmlst.org/paeruginosa/; Jolley & Maiden, 2010).
Implementation
We encapsulated the sequencing data processing routines in a
stand-alone package named seq2geno2pheno. The SVM classifi-
cation was conducted with Model-T, which is built on scikit-learn
(Pedregosa et al, 2011) and was already used as the prediction
engine in our previous work on bacterial trait prediction (Weimann
et al, 2016). seq2geno2pheno also implements a framework to use a
more broader set of classifiers, which we used to compare different
classification algorithms for drug resistance prediction. Finally, we
created a repository that includes scripts to re-produce the figures
and analyses presented in this paper using the aforementioned
packages.
Data availability
• RNA-Seq data: Gene Expression Omnibus GSE123544 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123544)
• Figure generation and analyses scripts: GitHub (https://github.
com/hzi-bifo/Predicting_PA_AMR_paper)
• Sequencing data processing and classifier comparison software:
GitHub (https://github.com/hzi-bifo/seq2geno2pheno)
• SVM classification software: GitHub (https://github.com/hzi-bifo/
Model-T)
• DNA-Seq data: Sequence Read Archive PRJNA526797 (https://
www.ncbi.nlm.nih.gov/sra/?term=PRJNA526797)
• Direct input for training the machine learning classifiers (genomic
features and resistance data tables): Zenodo https://doi.org/10.
5281/zenodo.3464542 (https://zenodo.org/record/3464542#.Xf
YShRtCeUk)
Expanded View for this article is available online.
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